Form 4: Doximity Interim PFO Sells Shares for Tax Cover

Doximity's Interim PFO and PAO, Siddharth Sitaram, exercised stock options, converted Class B shares to Class A, and sold a portion of Class A shares to cover tax obligations.

Summary

• Siddharth Sitaram, Interim PFO and PAO of Doximity, Inc., reported transactions on March 10, 2026.
• Exercised 5,000 stock options at an exercise price of $4.12 per share. These options were granted on December 22, 2020, with vesting starting November 23, 2021.
• Converted 5,000 shares of Class B Common Stock into 5,000 shares of Class A Common Stock.
• Sold 2,319 shares of Class A Common Stock at a price of $25.37 per share.
• The sale was a "sell-to-cover" transaction to satisfy tax withholding obligations related to the stock option exercise.
• This transaction was executed automatically pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2025.
• Following these transactions, Sitaram beneficially owns 84,132 shares of Class A Common Stock and 83,800 stock options for Class B Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it involves an insider selling shares, the sale is explicitly for tax purposes and executed under a pre-arranged 10b5-1 plan, which mitigates any negative sentiment typically associated with insider selling.

Positives

• The exercise of stock options indicates the executive is realizing value from their compensation package.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, suggesting a planned and not opportunistic sale.

Negatives

• An insider sale, even for tax purposes, reduces the executive's direct equity stake in the company.

Risks

• While a routine transaction, significant or frequent insider selling could be perceived as a lack of confidence by some investors, potentially impacting market sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales reported occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2025.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions by executives are a common practice in the technology and healthcare sectors, particularly for companies with significant equity-based compensation. These sales are typically pre-arranged under Rule 10b5-1 plans to manage tax liabilities upon option exercise or restricted stock unit vesting, and are generally not indicative of a change in the company's fundamental prospects or a lack of confidence by the executive.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with best practices for corporate governance, providing transparency and mitigating concerns about opportunistic insider trading, a standard adopted by many public companies across various industries.
• The exercise of stock options and subsequent sale to cover taxes is a routine event for executives in publicly traded companies, comparable to similar compensation-related transactions seen at peers like Teladoc Health (TDOC) or Amwell (AMWL) in the digital health space, or broader tech companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction is a routine insider compensation event and is unlikely to have a significant direct impact on the company's operational or financial performance.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The remaining stock options will continue to vest according to the original schedule, subject to the Reporting Person's continuous service relationship with the Issuer.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of stock options and a subsequent 'sell-to-cover' sale to satisfy tax obligations, executed under a pre-established 10b5-1 trading plan. Such transactions are common and generally do not signal a change in the company's fundamentals or management's long-term outlook. Therefore, a seasoned investor would likely maintain their current position, as this event provides no strong catalyst for a 'buy' or 'sell' decision.

Keywords

Doximity, DOCS, Form 4, insider trading, stock options, share sale, executive compensation, Rule 10b5-1